Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Liver Diseases

Free Subscription 21.10.2019 2 AJR Am J Roentgenol 1 Am J Pathol 1 Biochem Biophys Res Commun 2 BMC Cancer 1 Dig Dis 2 Dig Dis Sci 4 Gastroenterology 5 Gut 4 Hepatology 1 J Comput Assist Tomogr 1 J Gastroenterol 2 J Hepatol 1 J Pediatr 1 Lancet 3 Lancet Gastroenterol Hepatol 3 N Engl J Med 2 Oncogene 1 PLoS One 1 Radiology 2 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. VERNUCCIO F, Godfrey D, Meyer M, Williamson HV, et al
   Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.
   AJR Am J Roentgenol. 2019 Oct 15:1-8. doi: 10.2214/AJR.18.20842.
   PubMed     Text format     Abstract available
   
   
2. FALT T, Soderberg M, Horberg L, Christoffersen C, et al
   Simulated Dose Reduction for Abdominal CT With Filtered Back Projection Technique: Effect on Liver Lesion Detection and Characterization.
   AJR Am J Roentgenol. 2018 Oct 9:1-10. doi: 10.2214/AJR.17.19441.
   PubMed     Text format     Abstract available
   
   

   
   Am J Pathol

3. QI J, Kim JW, Zhou Z, Lim CW, et al
   Ferroptosis affects the progression of non-alcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice.
   Am J Pathol. 2019 Oct 11. pii: S0002-9440(19)30759.
   PubMed     Text format     Abstract available
   
   

   
   Biochem Biophys Res Commun

4. BO C, Li X, He L, Zhang S, et al
   A novel long noncoding RNA HHIP-AS1 suppresses hepatocellular carcinoma progression through stabilizing HHIP mRNA.
   Biochem Biophys Res Commun. 2019 Oct 8. pii: S0006-291X(19)31875.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

5. NATRI HM, Wilson MA, Buetow KH
   Distinct molecular etiologies of male and female hepatocellular carcinoma.
   BMC Cancer. 2019;19:951.
   PubMed     Text format     Abstract available
   
   
6. KONDO M, Morimoto M, Kobayashi S, Ohkawa S, et al
   Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
   BMC Cancer. 2019;19:954.
   PubMed     Text format     Abstract available
   
   

   
   Dig Dis

7. REICHERT MC, Schulz A, Massmann A, Buecker A, et al
   Predictive Power of Liver Maximum Function Capacity Test in Transjugular Intrahepatic Portosystemic Shunt Patients: A Pilot Study.
   Dig Dis. 2019 Oct 16:1-8. doi: 10.1159/000503098.
   PubMed     Text format     Abstract available
   
   

   
   Dig Dis Sci

8. EDELSON J, Suarez AL, Zhang J, Rockey DC, et al
   Sedation During Endoscopy in Patients with Cirrhosis: Safety and Predictors of Adverse Events.
   Dig Dis Sci. 2019 Oct 12. pii: 10.1007/s10620-019-05845.
   PubMed     Text format     Abstract available
   
   
9. WANG JH, Ou HY, Yen YH, Chen CH, et al
   Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference.
   Dig Dis Sci. 2019 Oct 15. pii: 10.1007/s10620-019-05883.
   PubMed     Text format     Abstract available
   
   

   
   Gastroenterology

10. CARUSO S, Nault JC
    A dive into the deep heterogeneity of hepatocellular carcinoma.
    Gastroenterology. 2019 Oct 10. pii: S0016-5085(19)41420.
    PubMed     Text format    
    
    
11. CHOUDHARY NS, Saraf N, Saigal S, Soin AS, et al
    Factors Associated With Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation: Unanswered Questions.
    Gastroenterology. 2019;157:1162-1163.
    PubMed     Text format    
    
    
12. WRIGHT GEB, Drogemoller BI, Ross CJD, Carleton BC, et al
    Genome-Wide Association Studies of Drug-Induced Liver Injury Make Progress Beyond the HLA Region.
    Gastroenterology. 2019;157:1167-1168.
    PubMed     Text format    
    
    
13. SUNDARAM V, Jalan R
    Reply.
    Gastroenterology. 2019;157:1163-1164.
    PubMed     Text format    
    
    

    
    Gut

14. CAUSSY C, Ajmera VH, Puri P, Hsu CL, et al
    Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
    Gut. 2019;68:1884-1892.
    PubMed     Text format     Abstract available
    
    
15. FOGLIA B, Parola M
    Of FACT complex and oxidative stress response: a KEAP1/NRF2-dependent novel mechanism sustaining hepatocellular carcinoma progression.
    Gut. 2019 Oct 15. pii: gutjnl-2019-319609. doi: 10.1136/gutjnl-2019-319609.
    PubMed     Text format    
    
    
16. KREMER AE, Le Cleac'h A, Lemoinne S, Wolf K, et al
    Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis.
    Gut. 2018 Sep 18. pii: gutjnl-2018-317426. doi: 10.1136/gutjnl-2018-317426.
    PubMed     Text format    
    
    
17. KORF H, du Plessis J, van Pelt J, De Groote S, et al
    Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity.
    Gut. 2019;68:1872-1883.
    PubMed     Text format     Abstract available
    
    
18. WANG D, Li X, Li J, Lu Y, et al
    APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression.
    Gut. 2019;68:1846-1857.
    PubMed     Text format     Abstract available
    
    

    
    Hepatology

19. SONG K, Kwon H, Han C, Chen W, et al
    YAP in Kupffer cells enhances the production of pro-inflammatory cytokines and promotes the development of non-alcoholic steatohepatitis.
    Hepatology. 2019 Oct 14. doi: 10.1002/hep.30990.
    PubMed     Text format     Abstract available
    
    
20. TANEJA V
    Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
    Hepatology. 2019 Oct 14. doi: 10.1002/hep.30992.
    PubMed     Text format     Abstract available
    
    
21. LEUNG CON, Tong M, Chung KPS, Zhou L, et al
    Overriding adaptive resistance to sorafenib via combination therapy with SHP2 blockade in hepatocellular carcinoma.
    Hepatology. 2019 Oct 14. doi: 10.1002/hep.30989.
    PubMed     Text format     Abstract available
    
    
22. HYDE AM, Carbonneau M, Abraldes JG, Tandon P, et al
    Advanced Practice Providers: Raising Our Defenses Against the Rising Tide of Cirrhosis.
    Hepatology. 2019 Oct 12. doi: 10.1002/hep.30987.
    PubMed     Text format     Abstract available
    
    

    
    J Comput Assist Tomogr

23. MATSUMOTO Y, Masuda T, Sato T, Arataki K, et al
    Contrast Material Injection Protocol With the Dose Determined According to Lean Body Weight at Hepatic Dynamic Computed Tomography: Comparison Among Patients With Different Body Mass Indices.
    J Comput Assist Tomogr. 2019;43:736-740.
    PubMed     Text format     Abstract available
    
    

    
    J Gastroenterol

24. ENOOKU K, Tsutsumi T, Kondo M, Fujiwara N, et al
    Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    J Gastroenterol. 2019 Oct 10. pii: 10.1007/s00535-019-01633.
    PubMed     Text format     Abstract available
    
    

    
    J Hepatol

25. LI Y, Tang L, Guo L, Chen C, et al
    CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+T cells favors viral control in chronic HBV infection.
    J Hepatol. 2019 Oct 11. pii: S0168-8278(19)30602.
    PubMed     Text format     Abstract available
    
    
26. GIANNELLI V, Roux O, Laouenan C, Manchon P, et al
    Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
    J Hepatol. 2019 Oct 14. pii: S0168-8278(19)30603.
    PubMed     Text format     Abstract available
    
    

    
    J Pediatr

27. HADZIC N, Cho SJ, Finegold MJ
    Hepatoblastoma surveillance in infants born with very low birth weight: Has the time come?
    J Pediatr. 2019 Oct 9. pii: S0022-3476(19)31156.
    PubMed     Text format    
    
    

    
    Lancet

28. STRAVITZ RT, Lee WM
    Acute liver failure.
    Lancet. 2019;394:869-881.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

29. D'HAENS G, Pinzani M
    Intestinal and hepatic fibrosis: how are they similar?
    Lancet Gastroenterol Hepatol. 2019;4:820-822.
    PubMed     Text format    
    
    
30. POSE E, Napoleone L, Amin A, Campion D, et al
    Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Gastroenterol Hepatol. 2019 Oct 10. pii: S2468-1253(19)30320.
    PubMed     Text format     Abstract available
    
    
31. SIMON TG
    When less is more: dosing simvastatin in decompensated cirrhosis.
    Lancet Gastroenterol Hepatol. 2019 Oct 10. pii: S2468-1253(19)30321.
    PubMed     Text format    
    
    

    
    N Engl J Med

32. RATHI S, Kumar P
    Drug-Induced Liver Injury - Types and Phenotypes.
    N Engl J Med. 2019;381:1395.
    PubMed     Text format    
    
    
33. GABBI C, Bertolotti M
    Drug-Induced Liver Injury - Types and Phenotypes.
    N Engl J Med. 2019;381:1395-1396.
    PubMed     Text format    
    
    
34. HOOFNAGLE JH, Bjornsson ES
    Drug-Induced Liver Injury - Types and Phenotypes. Reply.
    N Engl J Med. 2019;381:1396.
    PubMed     Text format    
    
    

    
    Oncogene

35. MARCHAND B, Pitarresi JR, Reichert M, Suzuki K, et al
    PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells.
    Oncogene. 2019;38:4325-4339.
    PubMed     Text format     Abstract available
    
    
36. ZHANGYUAN G, Wang F, Zhang H, Jiang R, et al
    VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.
    Oncogene. 2019 Oct 11. pii: 10.1038/s41388-019-1052.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

37. NISHIMURA T, Takami T, Sasaki R, Aibe Y, et al
    Liver regeneration therapy through the hepatic artery-infusion of cultured bone marrow cells in a canine liver fibrosis model.
    PLoS One. 2019;14:e0210588.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

38. CURTIS WA, Fraum TJ, An H, Chen Y, et al
    Quantitative MRI of Diffuse Liver Disease: Current Applications and Future Directions.
    Radiology. 2018 Dec 4:172765. doi: 10.1148/radiol.2018172765.
    PubMed     Text format     Abstract available
    
    

    
    Transplant Proc

39. INVERNIZZI F, Maggi U, Mazza S, Baia M, et al
    Focus on Very Late Hepatocellular Carcinoma Recurring After Liver Transplantation: A Case Report and Literature Review.
    Transplant Proc. 2019 Oct 10. pii: S0041-1345(19)30627.
    PubMed     Text format     Abstract available
    
    
40. LOFORTE A, Fiorentino M, Gliozzi G, Mariani C, et al
    Heart Transplant and Hepato-Renal Dysfunction: The Model of End-Stage Liver Disease Excluding International Normalized Ratio as a Predictor of Postoperative Outcomes.
    Transplant Proc. 2019 Oct 10. pii: S0041-1345(19)30967.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: